Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This retrospective study aimed to evaluate the distribution pattern and prognostic value of 21-gene recurrence score (RS) in Chinese patients with mucinous breast cancer (MC) and compared with infiltrating ductal carcinoma (IDC). Materials and Methods Patients diagnosed with MC or IDC from January 2010 to January 2017 were retrospectively recruited. Reverse transcriptase–polymerase chain reaction assay of 21 genes was conducted to calculate the RS. Univariate and multivariate analyses were performed to assess the association between RS and clinicopathological factors. Survival outcomes including disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier method and compared by log-rank test. Results The MC cohort included 128 patients and the IDC cohort included 707 patients. The proportions of patients with a low (RS < 18), intermediate (18-30), or high risk (RS > 30) were 32.0%, 48.4%, and 19.5% in MC cohort, and 26.9%, 46.8% and 26.3% in IDC cohort. The distribution of RS varied significantly according to different Ki-67 index and molecular subtype in both cohorts. Moreover, the receipt of chemotherapy was associated with RS in both cohorts. Among patients with MC, tumor stage was related to the DFS (p=0.040). No significant differences in DFS and OS were found among MC patients in different RS risk groups (OS, p=0.695; DFS, p=0.926). Conclusion RS was significantly related to Ki-67 index and molecular subtypes in MC patients, which is similar in IDC patients. However, RS was not able to predict DFS and OS in patients with MC.
Abstract
Purpose This retrospective study aimed to evaluate the distribution pattern and prognostic value of 21-gene recurrence score (RS) in Chinese patients with mucinous breast cancer (MC) and compared with infiltrating ductal carcinoma (IDC). Materials and Methods Patients diagnosed with MC or IDC from January 2010 to January 2017 were retrospectively recruited. Reverse transcriptase–polymerase chain reaction assay of 21 genes was conducted to calculate the RS. Univariate and multivariate analyses were performed to assess the association between RS and clinicopathological factors. Survival outcomes including disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier method and compared by log-rank test. Results The MC cohort included 128 patients and the IDC cohort included 707 patients. The proportions of patients with a low (RS < 18), intermediate (18-30), or high risk (RS > 30) were 32.0%, 48.4%, and 19.5% in MC cohort, and 26.9%, 46.8% and 26.3% in IDC cohort. The distribution of RS varied significantly according to different Ki-67 index and molecular subtype in both cohorts. Moreover, the receipt of chemotherapy was associated with RS in both cohorts. Among patients with MC, tumor stage was related to the DFS (p=0.040). No significant differences in DFS and OS were found among MC patients in different RS risk groups (OS, p=0.695; DFS, p=0.926). Conclusion RS was significantly related to Ki-67 index and molecular subtypes in MC patients, which is similar in IDC patients. However, RS was not able to predict DFS and OS in patients with MC.
참고문헌 (22)
- Paik S, "A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer", N Engl J Med, 351, pp.2817~2826 (2004)
- Dowsett M, "Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen : a TransATAC study", J Clin Oncol, 28, pp.1829~1834 (2010)
- Paik S, "Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer", J Clin Oncol, 24, pp.3726~3734 (2006)
- Albain KS, "Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy : a retrospective analysis of a randomised trial", Lancet Oncol, 11, pp.55~65 (2010)
- Komaki K, "Mucinous carcinoma of the breast in Japan. A prognostic analysis based on morphologic features", Cancer, 61, pp.989~996 (1988)
- Andre S, "Mucinous carcinoma of the breast : a pathologic study of 82 cases", J Surg Oncol, 58, pp.162~167 (1995)
- Diab SG, "Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas", J Clin Oncol, 17, pp.1442~1448 (1999)
- Li CI, "Clinical characteristics of different histologic types of breast cancer", Br J Cancer, 93, pp.1046~1052 (2005)
- Louwman MW, "Uncommon breast tumors in perspective : incidence, treatment and survival in the Netherlands", Int J Cancer, 121, pp.127~135 (2007)
- 박세호, "Clinicopathological Characteristics of Mucinous Carcinoma of the Breast in Korea: Comparison with Invasive Ductal Carcinoma-Not Otherwise Specified", Journal of Korean Medical Science, 25(3), pp.361~368 (2010), 대한의학회
- Ranade A, "Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern", J Clin Pathol, 63, pp.1043~1047 (2010)
- Soo Youn Bae, "Mucinous Carcinoma of the Breast in Comparison with Invasive Ductal Carcinoma: Clinicopathologic Characteristics and Prognosis", Journal of Breast Cancer, 14(4), pp.308~313 (2011), 한국유방암학회
- Hanagiri T, "Clinicopathologic characteristics of mucinous carcinoma of the breast", Int Surg, 95, pp.126~129 (2010)
- Barkley CR, "Mucinous breast carcinoma : a large contemporary series", Am J Surg, 196, pp.549~551 (2008)
- Wu J, "Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients", Oncotarget, 8, pp.38706~38716 (2017)
- Wang W, "Distribution and clinical utility of the 21-gene recurrence score in pure mucinous breast cancer patients : a case-control study", J Cancer, 9, pp.3216~3224 (2018)
- Chen X, "Surgery time interval and molecular subtype may influence Ki67change after core needle biopsy in breast cancer patients", BMC Cancer, 15, pp.822~ (2015)
- Zong Y, "Progesterone receptor status and Ki-67 index may predict early relapse in luminal B", HER2 negative breast cancer patients : a retrospective study, 2014, pp.9, e95629~
- Hammond ME, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, 2010, pp.28, 2784~2795
- Kizy S, "Distribution of 21-gene recurrence scores among breast cancer histologic subtypes", Arch Pathol Lab Med, 142, pp.735~741 (2018)
- Gluz O, "West German study Group Phase III PlanB Trial : first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment", J Clin Oncol, 34, pp.2341~2349 (2016)
- Di Saverio S, "A retrospective review with long term follow up of 11, 400 cases of pure mucinous breast carcinoma", Breast Cancer Res Treat, 111, pp.541~547 (2008)